Acute and sub-chronic oral toxicities of DA.AMLODEPON HVD hard capsule in experimental animals

Pham Thi Van Anh, Nguyen Van Dam, Nguyen Van Dat, Pham Thanh Ky, Nguyen Trong Thong, Dao Thi Ngoan, Dang Thi Thu Hien

Main Article Content

Abstract

Assessment of toxicities of DA.AMLODEPON HVD hard capsule on experimental animals. The acute toxicity of DA.AMLODEPON HVD was assessed on Swiss mice according to World Health Organization Guidance, and LD50 determination according to the method of Litchfield – Wilcoxon. The sub-chronic toxicity study of DA.AMLODEPON HVD at two doses (0.42 g/kg/day and 1.26g/kg/day) was conducted in rats for four consecutive weeks. After administration, general conditions and the body weight of rats were evaluated. Blood samples were collected for analyzing serum parameters before treatment (T0), second week (T1), and fourth week (T2). Histopathological analysis of livers and kidneys was observed at the end of the experiment. The results revealed that mice were taken up to a maximum dose of 39.15 g/kg with no symptoms of acute toxicity, LD50 of DA.AMLODEPON HVD has not been determined. The sub-chronic toxicity study at two doses did not change the body weight of rats, general conditions. The parameters for structures and functions of livers and kidneys and microscopic of the livers and kidneys are in a normal range during the study period.

Article Details

References

1. Cardiovascular diseases (CVDs). Accessed August 3, 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012;380(9859):2095-2128.
3. Amini M, Zayeri F, Salehi M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017. BMC Public Health. 2021;21(1):401.
4. Koleva T, Madzharova I, Baleva V, Dragoĭcheva T, Stoĭkova K. Side effects of cardiovascular drugs. Vutr Boles. 1989;28(5):24-30.
5. Shaito A, Thuan DTB, Phu HT, et al. Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety. Front Pharmacol. 2020;11:422.
6. Otari SV, Pawar SH, Patel SKS, et al. Canna edulis Leaf Extract-Mediated Preparation of Stabilized Silver Nanoparticles: Characterization, Antimicrobial Activity, and Toxicity Studies. J Microbiol Biotechnol. 2017;27(4):731-738.
7. World Health Organization. Working group on the safety and efficacy of herbal medicine. 2013.
8. Pemissi M, Metowogo K, Melila M, et al. Acute and subchronic oral toxicity assessments of Combretum micranthum (Combretaceae) in Wistar rats. Toxicol Rep. 2020;7:162-168.
9. Sugimoto Y, Furutani S, Itoh A, et al. Effects of extracts and neferine from the embryo of Nelumbo nucifera seeds on the central nervous system. Phytomedicine Int J Phytother Phytopharm. 2008;15(12):1117-1124.
10. He J-Y, Ma N, Zhu S, Komatsu K, Li Z-Y, Fu W-M. The genus Codonopsis (Campanulaceae): a review of phytochemistry, bioactivity and quality control. J Nat Med. 2015;69(1):1-21.
11. Chung H-S, Lee HJ, Shim I, Bae H. Assessment of anti-depressant effect of nelumbinis semen on rats under chronic mild stress and its subchronic oral toxicity in rats and beagle dogs. BMC Complement Altern Med. 2012;12(1):1046.
12. Sohn D-H, Kim Y-C, Oh S-H, Park E-J, Li X, Lee B-H. Hepatoprotective and free radical scavenging effects of Nelumbo nucifera. Phytomedicine. 2003;10(2-3):165-169.